cancer
Last updated: 2021-06-25

Lung Cancer Research: Osimertinib Data in EGFR-Mutant Lung Cancer

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Lung Cancer Research: Osimertinib Data in EGFR-Mutant Lung Cancer

Lung Cancer Research: Osimertinib Data in EGFR-Mutant Lung Cancer

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

For EGFR-mutant Non-Small Cell Lung Cancer (NSCLC), Osimertinib is a standard therapy. Its ability to cross the blood-brain barrier and target mutations has changed the treatment landscape.

1. Adjuvant Treatment Research: ADAURA

In the ADAURA trial, using Osimertinib as adjuvant therapy after surgery for early-stage (IB-IIIA) lung cancer was reported to reduce the risk of recurrence or death by 80% (literature data; for reference only).

2. Advanced/Metastatic Disease Research: FLAURA

As a first-line treatment for advanced cases, clinical trials reported longer overall survival (OS) with Osimertinib compared to older, first-generation TKIs (literature data; for reference only), with a better safety profile and fewer side effects like rash and diarrhea.

Medical Supporter: Expert Coordination for Japanese Oncology
As a former institution registered with the Ministry of Foreign Affairs of Japan, we facilitate expert consultations on the latest TKI protocols.

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.

Consult on LINE Contact an advisor
Fukuoka HQ: +81-92-984-3200
Formerly officially certified, No. B-066

Related Reading

Ropeginterferon Alfa-2b Receives FDA Approval for Polycythemia Vera

The FDA has approved ropeginterferon alfa-2b-njft (BESREMi Pen™) for polycythemia vera in the U.S. Here's what patients considering overseas treatment should know.

2026-06-24

Fujitsu Launches Digital Medical Certificate Service Adopted by Japan Cancer Institute Hospital

A new digital system connecting hospital documentation and insurance in Japan — what it means for patients considering cancer care at major Japanese centers.

2026-07-02

First FDA-Approved On-Body Injectable Anticancer Drug: What It Means for Patients

The FDA has granted its first approval for a wearable on-body injectable anticancer device. Here's what cancer patients considering treatment abroad should know.

2026-07-07

Enhertu Gets EU Approval as First Tumour-Agnostic HER2-Directed ADC

The EU has approved Enhertu for previously treated HER2-positive metastatic solid tumours — the first tumour-agnostic HER2-directed antibody drug conjugate approval. Here's what it means for patients considering treatment options.

2026-06-30